- Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe - Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 - Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief...
Read More Details
Finally We wish PressBee provided you with enough information of ( Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval )
Also on site :
- ‘Shadow Force’ Review: Two Spies Get Dragged From the Cold in Middling Action Opus
- UAE denies supplying Sudan paramilitaries with Chinese arms
- T.J. Maxx Is Selling a Luxury, Line-Smoothing Eye Cream for Less Than $20